NCT06631092 2026-02-20Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerNEC Bio B.VPhase 1/2 Recruiting12 enrolled
NCT02529930 2022-07-13An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)Nykode Therapeutics ASAPhase 1/2 Completed34 enrolled